Conclusions Together, once-weekly 2.4 mg semaglutide reduced all-cause mortality by 19%, CV deaths by 15%, and non-CV deaths by 23% among non-diabetic obese or overweight patients with CV disease
The appetite-suppressing effects of these medications, coupled with their ability to slow gastric emptying and induce a prolonged feeling of fullness, contribute to reduced food intake and subsequent weight reduction
L-carnitine versus niacinamide The tirzepatide niacinamide combination adds a form of vitamin B3 that supports NAD+ production, cellular energy, and skin health
N Engl J Med (2017) 377(7):64457
Alabamas contributory negligence rule is rarely a barrier in GLP-1 cases because liability centers on manufacturer failures to adequately warn patients of known gastrointestinal risks
J Am Soc Nephrol 2021;32:2352-61.ArticlePubMedPMC 58